Therapeutic potential of the anti‐angiogenesis drug TNP‐470
- 1 December 1998
- journal article
- review article
- Published by Wiley in International Journal of Experimental Pathology
- Vol. 79 (6) , 359-362
- https://doi.org/10.1046/j.1365-2613.1998.00087.x
Abstract
Neovessel formation is a pre-requisite for tumour growth and dissemination. Inhibition of angiogenesis is a promising approach for the treatment of neoplasms. In recent years, antiangiogenic drugs, such as TNP-470, have entered clinical trials. In this paper, we review the key experimental and clinical data on the role of TNP-470 in anti-tumour treatment.Keywords
This publication has 19 references indexed in Scilit:
- Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470New England Journal of Medicine, 1998
- Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470Nature Medicine, 1997
- Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agentsInvestigational New Drugs, 1997
- The Angiogenesis Inhibitor TNP-470 (AGM-1470) Improves Long-Term Survival of Rats with Liver MetastasisJournal of Surgical Research, 1996
- Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin c on the growth and liver metastasis of human colon cancerInternational Journal of Cancer, 1995
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470)British Journal of Cancer, 1994
- Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growthNature, 1990
- Transplacental Carcinogenesis by StilbestrolNew England Journal of Medicine, 1971